Collection of ENEA technology and expertise
Method for the production of antibodies biotechnologically fused with the peroxidase enzyme for diagnostics
The technology describes the method for obtaining already “modified” antibodies to be used as reagents for immunoenzymatic systems in diagnostics. Using the plant as a biofactory, as an alternative to animal cells, it is possible to produce antibodies linked, biotechnologically, with the enzyme peroxidase (HRP). Recombinant antibodies maintain both the ability to bind their target and the enzymatic function of peroxidase unaltered and can be used in any immunoenzymatic assay.
Application sectors
Problem to solve
In immunoenzymatic systems, antibodies are associated with the peroxidase enzyme, allowing, through a colorimetric reaction, to correlate the signal obtained with the quantity of molecules bound to the enzyme and therefore to detect and quantify the molecule of interest. Currently, antibodies and peroxidase enzymes are chemically conjugated, with a higher cost of preparation of diagnostic reagents and difficulty in standardizing the derived products. Both molecules (antibody and enzyme) must be individually produced and purified and then chemically conjugated. Naturally, each additional step in the production chain translates into an increase in the cost of the semi-finished product, and since chemical conjugation is not perfectly controllable and/or determinable, even the variability between production batches becomes a problem to be addressed at the end of production.
Description
Antibodies are basic reagents in many diagnostic systems. In immunoenzymatic systems, antibodies are associated with the peroxidase enzyme, which is able to develop a chemical reaction whose product is detectable, quantifiable and correlated to the molecules bound to it. Currently, antibodies and peroxidase enzymes are chemically conjugated, with a higher cost of preparation of diagnostic reagents and difficulty in standardizing the derived products. The technology described, and the subject of an ENEA patent, allows to obtain complete antibodies (IgG) conjugated, in a biotechnological way, with the peroxidase enzyme (HRP), producing them in a sustainable system such as the plant, for their direct use in immunoenzymatic assays. The methodology, validated on various antibodies, has the additional advantage of being able to be applied to diagnostic assays already developed for their technological implementation.
Innovative aspects and advantages
- Methodology applicable to already developed kits
- Production in plants, used as biofactory
- Reduced analysis times
- Reduced production and purification costs of diagnostic reagents
- Standardization and analytical reproducibility of batches
Technological Maturity 4
Strengths
- Cost
- Social/economic relevance
- Legal/regulatory content
- Efficiency/productivity/performance
- Innovation
Admissible applications
- Diagnostic kits based on antigen/antibody interaction and detection with peroxidase enzyme
- Production of semi-finished products for diagnostic tests of kit reagents (es. ELISA)
- Useful technology for biomedical, veterinary, environmental and agri-food diagnostics
Research group involved
Patent Available for Licensing
Disponibile per una licenza non esclusiva
Revision date
26-05-2025
Didn't find what you were looking for or would like more information about our partnerships and services?
